Cystic Fibrosis - References

Citations

  1. Elkins MR, et al. (2006). A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine, 354(3): 229-240.

  2. Wark P, McDonald VM. (2009). Nebulised hypertonic saline for cystic fibrosis. Cochrane Database of Systematic Reviews (2).

Other Works Consulted

  • ACOG Committee on Genetics (2002, reaffirmed 2006). Genetics and molecular testing. ACOG Technology Assessment in Obstetrics and Gynecology, 100(1): 193-211.

  • American Academy of Pediatrics (2009). Nutrition in cystic fibrosis. In RE Kleinman, ed., Pediatric Nutrition Handbook, 6th ed., pp. 1001-1020. Elk Grove Village, IL: American Academy of Pediatrics.

  • Balfour-Lynn IM, Welch K (2012). Inhaled corticosteroids for cystic fibrosis. Cochrane Database of Systematic Reviews (11).

  • Borowitz D, et al. (2009). Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. Journal of Pediatrics, 155(6): S73-S93.

  • Boucher RC, et al. (2010). Cystic fibrosis. In R Mason et al., eds., Murray and Nadel's Textbook of Respiratory Medicine, 5th ed., vol. 1, pp. 985-1022. Philadelphia: Saunders.

  • Dovey ME (2006). Cystic fibrosis. In FD Burg et al., eds., Current Pediatric Therapy, 18th ed., pp. 457-461. Philadelphia: Saunders Elsevier.

  • Elkins MR, et al. (2006). A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine, 354(3): 229-240.

  • Ernst MM, et al. (2011). Developmental and psychosocial issues in cystic fibrosis. Pediatric Clinics of North America, 58(4): 865-885.

  • Farrell PM, et al. (2008). Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. Journal of Pediatrics, 153(2): S4-S14.

  • Flume PA, et al. (2009). Cystic fibrosis pulmonary guidelines: Airway clearance therapies. Respiratory Care, 54(4): 522-537.

  • Flume PA, et al. (2009). Cystic fibrosis pulmonary guidelines: Treatment of pulmonary exacerbations. American Journal of Respiratory and Critical Care Medicine, 180(9): 802-808.

  • Grosse SD, et al. (2004). Newborn screening for cystic fibrosis: Evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR, 53(RR-13): 1-36.

  • Gustafsson PM, et al. (2008). Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis. Thorax, 63(2): 129-134.

  • Jones AP, Wallis C (2010). Dornase alfa for cystic fibrosis. Cochrane Database of Systematic Reviews (3).

  • Nash EF, et al. (2009). Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database of Systematic Reviews (1).

  • Organ Procurement and Transplantation Network (2013). Organ distribution: Allocation of thoracic organs, Policy 3.7. Available online: http://optn.transplant.hrsa.gov/policiesAndBylaws/policies.asp.

  • Ratjen F, McColley S (2012). Update in cystic fibrosis 2011. American Journal of Respiratory and Critical Care Medicine, 185(9): 933-936.

  • Southern KW, et al. (2009). Newborn screening for cystic fibrosis. Cochrane Database of Systematic Reviews (1).

  • Wark P, McDonald VM. (2009). Nebulised hypertonic saline for cystic fibrosis. Cochrane Database of Systematic Reviews (2).

WebMD Medical Reference from Healthwise
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.© 1995-2015 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.